A novel approach to management of nocturia in patients with benign prostatic hyperplasia Sengottayan VK et al. - The authors have assessed the usefulness of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in the management of refractory nocturia in patients with benign prostatic hyperplasia (BPH). Celecoxib was an effective treatment option for patients with BPH with nocturia. [more...]
